Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Kidney Medicine
|
October 5, 2020
Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Matthew S Davenport, Mark A Perazella, Jerry Yee, et al.
Kidney Medicine
|
February 19, 2021
Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Jeffrey C Weinreb, Roger A Rodby, Jerry Yee, et al.
Kidney Medicine
|
January 17, 2025
Renal Physiology Education via Podcast: Channel Your Enthusiasm
Melanie P Hoenig, Anna R Gaddy, Priti Meena, et al.
Radiology
|
January 22, 2020
Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Matthew S Davenport, Mark A Perazella, Jerry Yee, et al.
Diabetes Care
|
July 28, 2004
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease
Andrew J Palmer, Lieven Annemans, Stéphane Roze, et al.
Kidney International. Supplement
|
December 23, 2004
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria
Andrew J Palmer, Lieven Annemans, Stéphane Roze, et al.
Clinical Therapeutics
|
August 30, 2003
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy
Roger A Rodby, Chion Fang Chiou, Jeff Borenstein, et al.
Current Medical Research and Opinion
|
November 2, 2006
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension
Andrew J Palmer, William J Valentine, Daniel M D Tucker, et al.
Journal of the American Society of Nephrology : JASN
|
August 27, 2005
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations
Marc A Pohl, Samuel Blumenthal, Daniel J Cordonnier, et al.
Seminars in Arthritis and Rheumatism
|
April 7, 2012
Disease-specific patient reported outcome tools for systemic lupus erythematosus
Meenakshi Jolly, A Simon Pickard, Joel A Block, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Kidney Medicine
|
October 5, 2020
Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Matthew S Davenport, Mark A Perazella, Jerry Yee, et al.
Kidney Medicine
|
February 19, 2021
Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Jeffrey C Weinreb, Roger A Rodby, Jerry Yee, et al.
Kidney Medicine
|
January 17, 2025
Renal Physiology Education via Podcast: Channel Your Enthusiasm
Melanie P Hoenig, Anna R Gaddy, Priti Meena, et al.
Radiology
|
January 22, 2020
Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Matthew S Davenport, Mark A Perazella, Jerry Yee, et al.
Diabetes Care
|
July 28, 2004
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease
Andrew J Palmer, Lieven Annemans, Stéphane Roze, et al.
Kidney International. Supplement
|
December 23, 2004
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria
Andrew J Palmer, Lieven Annemans, Stéphane Roze, et al.
Clinical Therapeutics
|
August 30, 2003
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy
Roger A Rodby, Chion Fang Chiou, Jeff Borenstein, et al.
Current Medical Research and Opinion
|
November 2, 2006
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension
Andrew J Palmer, William J Valentine, Daniel M D Tucker, et al.
Journal of the American Society of Nephrology : JASN
|
August 27, 2005
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations
Marc A Pohl, Samuel Blumenthal, Daniel J Cordonnier, et al.
Seminars in Arthritis and Rheumatism
|
April 7, 2012
Disease-specific patient reported outcome tools for systemic lupus erythematosus
Meenakshi Jolly, A Simon Pickard, Joel A Block, et al.
Page
of 3